273 related articles for article (PubMed ID: 27838186)
1. Temporal Evolution and Dose-Volume Histogram Predictors of Visual Acuity After Proton Beam Radiation Therapy of Uveal Melanoma.
Polishchuk AL; Mishra KK; Weinberg V; Daftari IK; Nguyen JM; Cole TB; Quivey JM; Phillips TL; Char DH
Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):91-97. PubMed ID: 27838186
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for neovascular glaucoma after proton beam therapy of uveal melanoma: a detailed analysis of tumor and dose-volume parameters.
Mishra KK; Daftari IK; Weinberg V; Cole T; Quivey JM; Castro JR; Phillips TL; Char DH
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):330-6. PubMed ID: 23886415
[TBL] [Abstract][Full Text] [Related]
3. Visual Outcomes of Parapapillary Uveal Melanomas Following Proton Beam Therapy.
Thariat J; Grange JD; Mosci C; Rosier L; Maschi C; Lanza F; Nguyen AM; Jaspart F; Bacin F; Bonnin N; Gaucher D; Sauerwein W; Angellier G; Hérault J; Caujolle JP
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):328-335. PubMed ID: 27084650
[TBL] [Abstract][Full Text] [Related]
4. Proton therapy for uveal melanoma in 43 juvenile patients: long-term results.
Petrovic A; Bergin C; Schalenbourg A; Goitein G; Zografos L
Ophthalmology; 2014 Apr; 121(4):898-904. PubMed ID: 24405742
[TBL] [Abstract][Full Text] [Related]
5. Vision Loss Following Episcleral Brachytherapy for Uveal Melanoma: Development of a Vision Prognostication Tool.
Aziz HA; Singh N; Bena J; Wilkinson A; Singh AD
JAMA Ophthalmol; 2016 Jun; 134(6):615-20. PubMed ID: 27101414
[TBL] [Abstract][Full Text] [Related]
6. Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques.
Puusaari I; Heikkonen J; Kivelä T
Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3425-34. PubMed ID: 15452045
[TBL] [Abstract][Full Text] [Related]
7. Radiation Maculopathy After Proton Beam Therapy for Uveal Melanoma: Optical Coherence Tomography Angiography Alterations Influencing Visual Acuity.
Matet A; Daruich A; Zografos L
Invest Ophthalmol Vis Sci; 2017 Aug; 58(10):3851-3861. PubMed ID: 28763558
[TBL] [Abstract][Full Text] [Related]
8. Linear accelerator-based stereotactic fractionated photon radiotherapy as an eye-conserving treatment for uveal melanoma.
Akbaba S; Foerster R; Nicolay NH; Arians N; Bostel T; Debus J; Hauswald H
Radiat Oncol; 2018 Aug; 13(1):140. PubMed ID: 30071857
[TBL] [Abstract][Full Text] [Related]
9. Predictive risk factors for radiation retinopathy and optic neuropathy after proton beam therapy for uveal melanoma.
Seibel I; Cordini D; Hager A; Tillner J; Riechardt AI; Heufelder J; Davids AM; Rehak M; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1787-92. PubMed ID: 27376824
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of Proton Beam Therapy for Ocular Melanoma Using a Novel 3D Treatment Planning Technique.
Hartsell WF; Kapur R; Hartsell SO; Sweeney P; Lopes C; Duggal A; Cohen J; Chang J; Polasani RS; Dunn M; Pankuch M
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):353-359. PubMed ID: 27084652
[TBL] [Abstract][Full Text] [Related]
11. Corneal Substructure Dosimetry Predicts Corneal Toxicity in Patients With Uveal Melanoma Treated With Proton Beam Therapy.
Lee HJ; Stacey A; Klesert TR; Wells C; Skalet AH; Bloch C; Fung A; Bowen SR; Wong TP; Shibata D; Halasz LM; Rengan R
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):374-382. PubMed ID: 30763658
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy.
Mahdjoubi A; Najean M; Lemaitre S; Dureau S; Dendale R; Levy C; Rouic LL; Desjardins L; Cassoux N
Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):411-420. PubMed ID: 29116399
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of proton therapy for the treatment of uveal metastases.
Kamran SC; Collier JM; Lane AM; Kim I; Niemierko A; Chen YL; MacDonald SM; Munzenrider JE; Gragoudas E; Shih HA
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1044-50. PubMed ID: 25442038
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of treatment with stereotactic radiosurgery or proton beam therapy for choroidal melanoma.
Sikuade MJ; Salvi S; Rundle PA; Errington DG; Kacperek A; Rennie IG
Eye (Lond); 2015 Sep; 29(9):1194-8. PubMed ID: 26160531
[TBL] [Abstract][Full Text] [Related]
15. Conservation treatment of the eye: Conformal proton reirradiation for recurrent uveal melanoma.
Marucci L; Lane AM; Li W; Egan KM; Gragoudas ES; Adams JA; Collier JM; Munzenrider JE
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1018-22. PubMed ID: 16376492
[TBL] [Abstract][Full Text] [Related]
16. Visual outcomes of proton beam therapy for choroidal melanoma at a single institute in the Republic of Korea.
Jung SK; Park YH; Shin DH; Kim HS; Jung JH; Kim TH; Moon SH
PLoS One; 2020; 15(12):e0242966. PubMed ID: 33264363
[TBL] [Abstract][Full Text] [Related]
17. Dose-Response and Normal Tissue Complication Probabilities after Proton Therapy for Choroidal Melanoma.
Espensen CA; Kiilgaard JF; Appelt AL; Fog LS; Herault J; Maschi C; Caujolle JP; Thariat J
Ophthalmology; 2021 Jan; 128(1):152-161. PubMed ID: 32574763
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up after uveal melanoma charged particle therapy.
Char DH; Kroll SM; Castro J
Trans Am Ophthalmol Soc; 1997; 95():171-87; discussion 187-91. PubMed ID: 9440169
[TBL] [Abstract][Full Text] [Related]
19. Visual outcome of eyes with malignant melanoma of the uvea after ruthenium plaque radiotherapy.
Summanen P; Immonen I; Kivelä T; Tommila P; Heikkonen J; Tarkkanen A
Ophthalmic Surg Lasers; 1995; 26(5):449-60. PubMed ID: 8963860
[TBL] [Abstract][Full Text] [Related]
20. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients.
Shields CL; Shields JA; Cater J; Gündüz K; Miyamoto C; Micaily B; Brady LW
Arch Ophthalmol; 2000 Sep; 118(9):1219-28. PubMed ID: 10980767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
